Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.
Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.
复制标题
血小板与淋巴细胞比率在肝细胞癌中的预后作用：系统评价和荟萃分析
DOI：
10.18632/oncotarget.15281
复制
发表时间：
2017-04-04
期刊：
影响因子：
--
通讯作者：
Li J
中科院分区：
文献类型：
--
作者：
Zhao Y;Si G;Zhu F;Hui J;Cai S;Huang C;Cheng S;Fathy AH;Xiang Y;Li J
已有多项研究探讨了血小板与淋巴细胞比率（PLR）在肝细胞癌（HCC）中的预后意义，然而，大多数报告的结果相互矛盾。为此，我们提出了一个系统的审查，旨在总结PLR在肝癌患者的预后意义。共确定了10项研究，共涉及2，315例患者。每项纳入研究的Newcastle-Ottawa质量评估量表（NOS）均大于或等于5。结果表明，与低PLR相比，高PLR与更差的OS显著相关（HR = 1.60，95% CI = 1.23 - 2.08，p = 0.0005; I2 = 88%，p < 0.00001）。在分析模型、临界值、种族、样本量和治疗的亚组分析中检测到相似的结果。然而，在HCC患者中未观察到PLR与DFS/RFS之间的明显相关性（HR = 1.21，95% CI = 0.87 - 1.67，p = 0.26; I2 = 61%，p = 0.07）。在PubMed、科克伦图书馆和Embase数据库中进行了完整的文献检索。回顾性和前瞻性研究集中在PLR对肝癌预后的作用，都被认为是“适合”我们的范围。确定的终点为：总生存期（OS）、无病生存期（DFS）、无复发生存期（RFS）和无进展生存期（PFS）。该研究表明，高PLR是HCC患者OS的不利预测因素，高PLR是HCC的有希望的预后生物标志物，特别是对于亚洲患者。
Several studies were conducted to explore the prognostic significance of platelet to lymphocyte ratio (PLR) in hepatocellular carcinoma (HCC), however, contradictory results across most reports were documented. To this end, we present a systematic review that aims to summarize the prognostic significance of PLR in patients with HCC. A total of 10 studies involving a total of 2,315 patients were identified. The Newcastle-Ottawa Quality Assessment Scale (NOS) of each included study was greater than or equal to 5. The results indicated that high PLR was significantly associated with a worse OS when compared to the low PLR (HR = 1.60, 95% CI = 1.23−2.08, p = 0.0005; I2 = 88%, p < 0.00001). Similar results were detected in the subgroup analysis of the analysis model, cut-off value, ethnicity, sample size and therapy. However, no obvious correlation between the PLR and DFS/RFS in patients with HCC was observed (HR = 1.21, 95% CI = 0.87−1.67, p = 0.26; I2 = 61%, p = 0.07). A complete literature search in the PubMed, Cochrane Library and Embase database was performed. Retrospective and prospective studies focusing on the role of PLR on the prognosis in HCC were all deemed as “suitable” for our scope. The endpoints determined were: the overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS) and the progress free survival (PFS). The study revealed that high PLR is an unfavorable predictor of OS in patients with HCC, and high PLR is a promising prognostic biomarker for HCC, especially for patients in Asia.